/STAA
STAA Stock - STAAR Surgical Company
Healthcare|Medical - Instruments & SuppliesNASDAQ
$25.14+4.66%
+$1.12 (+4.66%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).87
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+18.7%upside
Target: $29.84
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STAA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$24.89 – $25.39
TARGET (TP)$29.83
STOP LOSS$23.13
RISK/REWARD1:2.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.01
52W High$30.81
52W Low$13.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $313.90M | $322.42M | $284.39M | $230.47M | $163.46M |
| Gross Profit | $239.58M | $252.65M | $223.38M | $178.64M | $118.36M |
| Gross Margin | 76.3% | 78.4% | 78.5% | 77.5% | 72.4% |
| Operating Income | $-12,611,000 | $28.10M | $43.80M | $33.34M | $6.77M |
| Net Income | $-20,208,000 | $21.35M | $39.66M | $27.51M | $5.91M |
| Net Margin | -6.4% | 6.6% | 13.9% | 11.9% | 3.6% |
| EPS | $-0.41 | $0.44 | $0.83 | $0.52 | $0.13 |
Company Overview
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
35%
Hold / Neutral
11
65%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
6 Bullish11 Neutral/Bearish
Price Targets
$54
Average Target
↑ 115.7% Upside
Now
$17
Low
$54
Average
$91
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 21st 2025 | Wells Fargo | Initiation | Equal Weight | $17 |
| February 12th 2025 | Jefferies | Downgrade | Hold | - |
| February 12th 2025 | Mizuho | Downgrade | Neutral | $17← $45 |
| February 12th 2025 | BTIG Research | Downgrade | Neutral | - |
| February 12th 2025 | William Blair | Downgrade | Market Perform | - |
| July 15th 2024 | Morgan Stanley | Downgrade | Underweight | $37← $50 |
| June 11th 2024 | BTIG Research | Upgrade | Buy | $46 |
| March 11th 2024 | Stifel | Upgrade | Buy | $50← $30 |
| December 5th 2023 | Needham | Downgrade | Hold | - |
| December 4th 2023 | Morgan Stanley | Initiation | Equal Weight | $35 |
| September 15th 2023 | The Benchmark Company | Downgrade | Hold | - |
| August 3rd 2023 | Canaccord Genuity | Downgrade | Hold | $48← $77 |
| June 7th 2023 | William Blair | Downgrade | Market Perform | - |
| April 17th 2023 | Piper Sandler | Initiation | Neutral | $65 |
| February 6th 2023 | BTIG Research | Downgrade | Neutral | - |
Earnings History & Surprises
STAABeat Rate
94%
Last 18 quarters
Avg Surprise
-76.7%
EPS vs Estimate
Beats / Misses
17/1
Last 12 quarters
Latest EPS
$0.46
Q4 2025
EPS Surprise History
Q1 24
+26.3%
$0.24vs$0.19
Q2 24
+20.0%
$0.06vs$0.05
Q3 24
+32.0%
$0.33vs$0.25
Q4 24
+94.7%
$0.37vs$0.19
Q1 25
-2600.0%
$-0.50vs$0.02
Q2 25
+11.9%
$-0.52vs$-0.59
Q3 25
+87.5%
$-0.07vs$-0.56
Q4 25
+155.6%
$0.46vs$0.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $0.14 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.18 | $0.46 | +155.6% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.56 | $-0.07 | +87.5% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.59 | $-0.52 | +11.9% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $0.02 | $-0.50 | -2600.0% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $0.19 | $0.37 | +94.7% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.25 | $0.33 | +32.0% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $0.19 | $0.24 | +26.3% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.20 | $0.30 | +50.0% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.32 | $0.40 | +25.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.11 | $0.18 | +63.6% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $0.05 | $0.12 | +140.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.21 | $0.37 | +76.2% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $0.25 | $0.42 | +68.0% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $0.16 | $0.29 | +81.2% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.16 | $0.19 | +18.8% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.16 | $0.21 | +31.2% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.08 | $0.27 | +237.5% | ✓ BEAT |
Latest News
Alcon Exercises Merger Rights, Forcing STAAR Surgical To Adjourn Shareholder Vote To January 6, 2026
📉 NegativeBenzinga•Dec 19, 2025, 04:44 PM•Also:
Broadwood Partners Slams Alcon–STAAR Deal, Flag Sale Process Concerns
📉 NegativeBenzinga•Dec 16, 2025, 12:08 PM•Also:
Reported Earlier, Independent Proxy Firm ISS Recommends Approval Of STAAR Surgical's Merger With Alcon
📈 PositiveBenzinga•Dec 16, 2025, 06:39 AM•Also:
STAAR Surgical gains as proxy adviser ISS supports revised Alcon deal
📈 PositiveSeeking Alpha•Dec 16, 2025, 12:30 AM•Also:
Broadwood Slams STAAR–Alcon Deal as Flawed and Unfair to Shareholders
📉 NegativeBenzinga•Dec 11, 2025, 12:12 PM•Also:
Wells Fargo Maintains Equal-Weight on Staar Surgical, Raises Price Target to $30.75
➖ NeutralBenzinga•Dec 10, 2025, 08:15 PM
Major Shareholder Rejects STAAR Surgical's Sale to Alcon Despite Higher $30.75 Offer
📉 NegativeBenzinga•Dec 10, 2025, 12:10 PM•Also:
Broadwood Partners, 30.2% Stake Holders, Opposes Alcon's STAAR Surgical Acquisition; Says Calls Price Bump "Insufficient" And Sale Process Deeply Flawed
📉 NegativeBenzinga•Dec 9, 2025, 06:05 PM•Also:
STAAR Surgical shares are trading higher after Alcon amended its merger agreement to acquire the company for $30.75 per share in cash.
📈 PositiveBenzinga•Dec 9, 2025, 01:33 PM•Also:
Alcon Enters Amended Merger Agreement For Acquisition Of STAAR Surgical, will Purchase All Outstanding STAAR Shares For $30.75/Share In Cash, Representing Additional $150M In Equity Value
📈 PositiveBenzinga•Dec 9, 2025, 01:32 PM•Also:
STAAR Surgical Agrees With Alcon To Amend Merger Agreement To Allow Proactive Solicitation By STAAR Of Third-Party Proposals To Maximize Value For All STAAR Stockholders
📈 PositiveBenzinga•Nov 7, 2025, 03:13 PM•Also:
Staar Surgical Q3 EPS $0.18 Beats $0.16 Estimate, Sales $94.732M Beat $90.820M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:43 PM
Broadwood Seeks to Replace STAAR Surgical Directors, Citing Lost Shareholder Trust
📉 NegativeBenzinga•Oct 22, 2025, 10:19 AM
Yunqi Capital Reiterates Opposition To STAAR Surgical's Proposed Sale To Alcon, Urges Shareholders To Vote 'Against' Merger
📉 NegativeBenzinga•Oct 20, 2025, 09:33 PM•Also:
Broadwood, ISS, Glass Lewis, And Egan-Jones To Oppose STAAR Surgical's Proposed Sale; Telling Shareholders To Vote 'Against' Acquisition Over Flawed Process, Timing, and Price
📉 NegativeBenzinga•Oct 20, 2025, 12:45 PM
STAAR Surgical Says That No Acquisition Proposals Have Been Received From Any Party Other Than Alcon; Alcon Is Paying STAAR Stockholders A 59% Premium To STAAR's 90-Day Volume Weighted Average Price As Of August 4, 2025, Representing Compelling, Certain, And Immediate Cash Value
📈 PositiveBenzinga•Oct 16, 2025, 08:18 PM•Also:
STAAR Surgical holders should vote against sale to Alcon, ISS says - report
📉 NegativeSeeking Alpha•Oct 15, 2025, 03:31 PM•Also:
Broadwood Partners Urges STAAR Surgical Shareholders To Vote "AGAINST" Alcon Merger, Citing Fiduciary Breach And Undisclosed Acquisition Interest By CEO
📉 NegativeBenzinga•Oct 10, 2025, 05:19 PM•Also:
Yunqi Capital Urges Shareholders To Reject STAAR Surgical's Proposed Sale To Alcon; Cites Undervalued Offer, Misaligned CEO Incentives, And Strong Long-Term Prospects
📉 NegativeBenzinga•Oct 6, 2025, 08:24 PM•Also:
Broadwood Partners Urges Shareholders To Vote "AGAINST" STAAR's $28/Share Sale, Citing Rejection Of $58/Share Offer Last Year As Evidence Of Poor Board Judgment
📉 NegativeBenzinga•Oct 6, 2025, 12:30 PM•Also:
Frequently Asked Questions about STAA
What is STAA's current stock price?
STAAR Surgical Company (STAA) is currently trading at $25.14 per share. The stock has moved +4.66% today.
What is the analyst price target for STAA?
The average analyst price target for STAA is $29.83, based on 1 analyst.
What sector is STAAR Surgical Company in?
STAAR Surgical Company operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is STAA's market cap?
STAAR Surgical Company has a market capitalization of $1.24 billion, making it a small-cap company.
Does STAA pay dividends?
No, STAAR Surgical Company does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTA
Azenta, Inc.
$34.43
Mkt Cap: $1.6B
BBNX
Beta Bionics, Inc.
$29.25
Mkt Cap: $1.3B
BLFS
BioLife Solutions, Inc.
$25.07
Mkt Cap: $1.2B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$27.32
Mkt Cap: $1.6B
NVCR
NovoCure Limited
$12.84
Mkt Cap: $1.4B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
PLSE
Pulse Biosciences, Inc.
$15.26
Mkt Cap: $1.0B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to STAA for comparison